Pneumococcal conjugated vaccines: Impact of PCV-7 and new achievements in the postvaccine era

Expert Review of Vaccines

Volumn 7, Issue 9, 2008, Pages 1367-1394

  Dinleyici, Ener Cagri ^a   Yargic, Zeynel Abidin ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

13 valent vaccine; Invasive pneumococcal disease; PCV; PHiD CV; Pneumococcal conjugated vaccine; Pneumococcal disease; Serotype replacement; Seven valent conjugated pneumococcal vaccine; Ten valent vaccine; Vaccine efficacy

Indexed keywords

HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; CLINICAL TRIAL; DRUG CONJUGATION; GEOGRAPHICAL VARIATION (SPECIES); HEALTH PROGRAM; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION CONTROL; LOBAR PNEUMONIA; MORTALITY; OTITIS MEDIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION;

HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 55849129919     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.9.1367     Document Type: Review

References (173)

1. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol. Rec. 82(12), 93-104 (2007).
2. Cherian T. WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva. Vaccine 25(36), 6557-6564 (2007).
3. Levine OS, O'Brien KL, Knoll M et al. Pneumococcal vaccination in developing countries. Lancet 367(9526), 1880-1882 (2006).
4. Austrian R. Pneumococcal otitis media and pneumococcal vaccines, a historical perspective. Vaccine 19(Suppl. 1), S71-S77 (2000).
5. Makela PH, Butler JC. History of pneumococcal immunization. In: Pneumococcal Vaccines. Siber GR, Klugman KP, Makela PH (Eds). ASM Press, Washington DC, USA 19-29 (2008).
6. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect. Dis. 7(9), 597-606 (2007).
7. Goldblatt D, Assari T, Snapper C. The immunobiology of polysaccharide and conjugate vaccines. In: Pneumococcal Vaccines. Siber GR, Klugman KP, Makela PH (Eds). ASM Press, Washington, DC, USA 67-82 (2008).
8. 197 and PCV?7 outer-membrane protein complex.
9. Kilpi T, Ahman H, Jokinen J et al. (Finnish Otitis Media Study Group). Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37(9), 1155-1164 (2003).
10. Ekström N, Väkeväinen M, Verho J, Kilpi T, Käyhty H. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect. Immun. 75(4), 1794-1800 (2007).
11. Ekström N, Ahman H, Verho J et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect. Immun. 73(1), 369-377 (2005).
12. Dagan R, Givon-Lavi N, Zamir O et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis. 185(7), 927-936 (2002).
13. Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr. Infect. Dis. J. 22(6), 532-540 (2003).
14. Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin. Infect. Dis. 40(10), 1511-1518 (2005).
15. Madhi SA, Adrian P, Kuwanda L et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 25(13), 2451-2457 (2007).
16. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349(14), 1341-1348 (2003). •• One of the largest randomized clinical trials of conjugated pneumococcal vaccine, conducted in South Africa and describes vaccine efficacy in children with or without HIV.
17. Huebner RE, Mbelle N, Forrest B, Madore DV, Klugman KP. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr. Infect. Dis. J. 21(11), 1004-1007 (2002).
18. Cutts FT, Zaman SM, Enwere G et al. Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365(9465), 1139-1146 (2005). • Demonstrates the vaccine efficacy against radiologically confirmed pneumonia and showed 14% efficacy of vaccine preventing all-cause child mortality.
19. Wuorimaa T, Dagan R, Eskola J et al. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr. Infect. Dis. J. 20(3), 272-277 (2001).
20. Puumalainen T, Dagan R, Wuorimaa T et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr. Infect. Dis. J. 22(2), 141-149 (2003).
21. Dagan R, Kayhty H, Wuorimaa T et al. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr. Infect. Dis. J. 23(2), 91-98 (2004).
22. Lucero MG, Puumalainen T, Ugpo JM, Williams G, Käyhty H, Nohynek H. Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus-conjugated vaccine: a randomized controlled trial. J. Infect. Dis. 189(11), 2077-2084 (2004).
23. Capeding MZ, Puumalainen T, Gepanayao CP, Käyhty H, Lucero MG, Nohynek H. Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein - conjugated pneumococcal vaccine in Filipino infants. BMC Infect. Dis. 3, 17 (2003).
24. Puumalainen T, Ekström N, Zeta-Capeding R et al. Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine. J. Infect. Dis. 187(11), 1704-1708 (2003)
25. Puumalainen T, Zeta-Capeding MR, Käyhty H et al. Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants. Pediatr. Infect. Dis. J. 21(4), 309-314 (2002).
26. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 49(RR-9) 1-35 (2000).
27. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb. Mortal. Wkly. Rep. 57(13), 343-3444 (2008).
28. Whitney CG. Impact of conjugate pneumococcal vaccines. Pediatr. Infect. Dis. J. 24(8), 729-730 (2005).
29. Whitney CG, Pilishvili T, Farley MM et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368(9546), 1495-1502 (2006).
30. Haber M, Barskey A, Baughman W et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25(29), 5390-5398 (2007).
31. Poehling KA, Talbot TR, Griffin MR et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295(14), 1668-1674 (2006).
32. O'Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 21(17-18), 1815-1825 (2003).
33. Pelton SI, Dagan R, Gaines BM et al. Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 21(15), 1562-1571 (2003).
34. O'Brien KL, Santosham M. Potential impact of conjugate pneumococcal vaccines on pediatric pneumococcal diseases. Am. J. Epidemiol. 159(7), 634-644 (2004).
35. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19(3), 187-195 (2000). •• Describes the findings of one of the largest trials evaluating the vaccine efficacy in the USA.
36. Klugman KP, Cutts F, Adegbola R et al. Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease. In: Pneumococcal Vaccines. Siber GR, Klugman KP, Makela PH (Eds). ASM Press, Washington, DC, USA 317-326 (2008).
37. O'Brien KL, Moulton LH, Reid R et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362(9381), 355-361 (2003).
38. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348(18), 1737-1746 (2003).
39. Black SB, Shinefield H, Elvin L, Ray P, Lewis E, Fireman B. Impact of the introduction of pneumococcal conjugate vaccine on the epidemiology of invasive disease in children and adults within Northern California Kaiser Permanente (NCKP), Presented at: 41st Annual Meeting of the Infectious Disease Society of America, San Diego, CA, USA, 9-12 October 2003.
40. Kaplan SL, Mason EO Jr, Wald ER et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113(3 Pt 1), 443-449 (2004).
41. Talbot TR, Poehling KA, Hartert TV et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine. Clin. Infect. Dis. 39(5), 641-648 (2004).
42. Black S, Shinefield H, Baxter R et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis. J. 23(6), 485-489 (2004).
43. Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J; Massachusetts Department of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr. Infect. Dis. J. 24(1), 17-23 (2005).
44. Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294(16), 2043-2051 (2005).
45. Haddy RI, Perry K, Chacko CE et al. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr. Infect. Dis. J. 24(4), 320-323 (2005).
46. Lin PL, Michaels MG, Janosky J, Ortenzo M, Wald ER, Mason EO Jr. Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after licensure of the pneumococcal conjugate vaccine. Pediatrics 111(4 Pt 1), 896-869 (2003).
47. Herz AM, Greenhow TL, Alcantara J et al. Changing epidemiology of outpatient bacteremia in 3- to 36?month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr. Infect. Dis. J. 25(4), 293-300 (2006).
48. Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26(6), 468-472 (2007).
49. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin. Infect. Dis. 44(12), 1569-1576 (2007).
50. Messina AF, Katz-Gaynor K, Barton T et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr. Infect. Dis. J. 26(6), 461-467 (2007).
51. Black S, France EK, Isaacman D et al. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26(9), 771-777 (2007).
52. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb. Mortal. Wkly. Rep. 57(6), 144-148 (2008).
53. Tsai CJ, Griffin MR, Nuorti JP, Grijalva CG. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin. Infect. Dis. 46(11), 1664-1672 (2008).
54. Schuchat A, Pilishvili T, Farley M et al. Near elimination of vaccine-type invasive pneumococcal disease in U.S. following conjugate vaccine implementation, 1998-2006. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
55. Stephens DS, Zughaier SM, Whitney CG et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 365(9462), 855-863 (2005).
56. Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297(16), 1784-1792 (2007).
57. Roche PW, Krause V, Cook H et al. Invasive pneumococcal disease in Australia, 2006. Commun. Dis. Intell. 32(1), 18-30 (2008).
58. Giele C, Moore H, Bayley K et al. Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia? Vaccine 25(13), 2379-2384 (2007).
59. Dubos F, Marechal I, Husson MO, Courouble C, Aurel M, Martinot A; Hospital Network for Evaluating the Management of Common Childhood Diseases. Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France. Arch. Dis. Child. 92(11), 1009-1012 (2007).
60. Bingen E, Levy C, Varon E et al. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur. J. Clin. Microbiol. Infect. Dis. 27(3), 191-199 (2008).
61. Lernout T, Hanquet G, Verhaegen J. Epidemiology of invasive pneumococcal disease after introduction of the conjugate vaccine: the Belgian experience. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
62. Van der Ende A, Spanjaard L. The epidemiology of invasive pneumococcal disease in The Netherlands one year after the introduction of the heptavalent pneumococcal conjugate vaccine. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases, Reykjavik, Iceland, 8-12 June 2008.
63. Vestrheim DF, Lovoll O, Aaberge IS et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26(26), 3277-3281 (2008).
64. Aristegui J, Bernaola E, Pocheville I et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 26(5), 303-310 (2007).
65. Calbo E, Díaz A, Cañadell E et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin. Microbiol. Infect. 12(9), 867-872 (2006).
66. Barricarte A, Castilla J, Gil-Setas A et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin. Infect. Dis. 44(11), 1436-1441 (2007).
67. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 46(2), 174-182 (2008).
68. Sazawal S, Black RE; Pneumonia Case Management Trials Group. Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials. Lancet. Infect. Dis. 3(9), 547-556 (2003).
69. Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21(9), 810-815 (2002).
70. Hansen J, Black S, Shinefield H et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr. Infect. Dis. J. 25(9), 779-781 (2006).
71. Madhi SA, Heera JR, Kuwanda L, Klugman KP. Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia. PLoS Med. 2(2), e38 (2005).
72. Madhi SA, Klugman KP; Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med. 10(8), 811-813 (2004).
73. Puumalainen T, Williams G, Lupisan S. Use of chest radiograph, C-reactive protein (CRP), procalcitonin (PCT) and clinical markers to evaluate the efficacy of an investigational 11-valent pneumococcal conjugate vaccine (11PCV) against childhood pneumonia. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
74. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369(9568), 1179-1186 (2007).
75. Moore M, Pilishvili T, Farley MM. Trends in invasive pneumococcal pneumonia, selected U.S. Sites, 1998-2006. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
76. Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr. Infect. Dis. J. 23(8), 732-738 (2004).
77. O'Brien KL, David AB, Chandran A et al. Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatr. Infect. Dis. J. 27(1), 71-73 (2008).
78. Prymula R, Peeters P, Chrobok V et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367(9512), 740-748 (2006). •• Demonstrates the efficacy of 11-valent pneumococcal vaccine conjugated to protein D as a reduction of all clinical episodes of acute otitis media, culture?confirmed bacterial episodes, otitis media caused by nontypeable Haemophilus influenzae.
79. Palmu A, Jokinen J, Kilpi T; Finnish Otitis Media Study Group. Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine. Vaccine 26(20), 2466-2470 (2008).
80. Block SL, Hedrick J, Harrison CJ et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr. Infect. Dis. J. 23(9), 829-833 (2004).
81. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr. Infect. Dis. J. 23(9), 824-828 (2004).
82. Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr. Infect. Dis. J. 23(12), 1142-1152 (2004).
83. Pichichero ME, Casey JR. Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era. Pediatr. Infect. Dis. J. 26(10 Suppl.), S12-S16 (2007).
84. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 121(2), 253-260 (2008).
85. Grijalva CG, Poehling KA, Nuorti JP et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118(3), 865-873 (2006).
86. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22(1), 10-16 (2003).
87. Esposito S, Lizioli A, Lastrico A et al. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. Respir. Res. 8, 12 (2007).
88. Poehling KA, Szilagyi PG, Grijalva CG et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119(4), 707-715 (2007).
89. Veenhoven R, Bogaert D, Uiterwaal C et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 361(9376), 2189-2195 (2003).
90. van Heerbeek N, Straetemans M, Wiertsema SP et al. Effect of combined pneumococcal conjugate and polysaccharide vaccination on recurrent otitis media with effusion. Pediatrics 117(3), 603-608 (2006).
91. van Kempen MJ, Vermeiren JS, Vaneechoutte M et al. Pneumococcal conjugate vaccination in children with recurrent acute otitis media: a therapeutic alternative? Int. J. Pediatr. Otorhinolaryngol. 70(2), 275-285 (2006).
92. McEllistrem MC, Adams JM, Patel K et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin. Infect. Dis. 40(12), 1738-1744 (2005).
93. Brouwer CN, Maillé AR, Rovers MM et al. Effect of pneumococcal vaccination on quality of life in children with recurrent acute otitis media: a randomized, controlled trial. Pediatrics 115(2), 273-279 (2005).
94. Le TM, Rovers MM, Veenhoven RH, Sanders EA, Schilder AG. Effect of pneumococcal vaccination on otitis media with effusion in children older than 1 year. Eur. J. Pediatr. 166(10), 1049-1052 (2007).
95. Dagan R, Melamed R, Muallem M et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J. Infect. Dis. 174(6), 1271-1278 (1996).
96. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr. Infect. Dis. J. 16(11), 1060-1064 (1997).
97. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180(4), 1171-1176 (1999).
98. 197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatr. Infect. Dis. J. 19(5), 463-469 (2000).
99. Yeh SH, Zangwill KM, Lee H et al. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants. Vaccine 21(19-20), 2627-2631 (2003).
100. Veenhoven RH, Bogaert D, Schilder AG et al. Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. Clin. Infect. Dis. 39(7), 911-919 (2004).
101. O'Brien KL, Millar EV, Zell ER et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196(8), 1211-1220 (2007).
102. Lakshman R, Murdoch C, Race G, Burkinshaw R, Shaw L, Finn A. Pneumococcal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infancy. Arch. Dis. Child. 88(3), 211-214 (2003).
103. Ghaffar F, Barton T, Lozano J et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin. Infect. Dis. 39(7), 930-938 (2004).
104. Moore MR, Hyde TB, Hennessy TW et al. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska. J. Infect. Dis. 190(11), 2031-2038 (2004).
105. Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr. Infect. Dis. J. 23(11), 1015-1022 (2004).
106. Frazao N, Brito-Avo A, Simas C et al. Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug resistance of Streptococcus pneumoniae in healthy children attending day-care centers in Lisbon. Pediatr. Infect. Dis. J. 24(3), 243-252 (2005).
107. Hennessy TW, Petersen KM, Bruden D et al. Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: a controlled intervention trial in rural Alaska. Clin. Infect. Dis. 34(12), 1543-1550 (2002).
108. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116(3), e408-e413 (2005).
109. Cohen R, Levy C, de La Rocque F et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr. Infect. Dis. J. 25(11), 1001-1007 (2006).
110. Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, Chonmaitree T. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 117(5), 1823-1829 (2006).
111. Millar EV, O'Brien KL, Watt JP et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin. Infect. Dis. 43(1), 8-15 (2006).
112. Madhi SA, Adrian P, Kuwanda L, Cutland C, Albrich WC, Klugman KP. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae - and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization - in HIV-infected and HIV-uninfected children. J. Infect. Dis. 196(11), 1662-1666 (2007).
113. Kellner JD, Scheifele D, Vanderkooi OG, Macdonald J, Church DL, Tyrrell GJ. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr. Infect. Dis. J. 27(6), 526-532 (2008).
114. Park SY, Moore MR, Bruden DL et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr. Infect. Dis. J. 27(4), 335-340 (2008).
115. Grivea IN, Panagiotou M, Tsantouli AG, Syrogiannopoulos GA. Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr. Infect. Dis. J. 27(6), 519-525 (2008).
116. Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr. Infect. Dis. J. 22(6), 524-532 (2003).
117. Hammitt LL, Bruden DL, Butler JC et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J. Infect. Dis. 193(11), 1487-1494 (2006).
118. Metlay JP, Fishman NO, Joffe M, Edelstein PH. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 24(4), 468-475 (2006).
119. Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr. Infect. Dis. J. 20(10), 951-958 (2001).
120. Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354(14), 1455-1463 (2006). • Demonstrated the potential benefits of PCV?7 on antibiotic resistance.
121. Hanage WP, Huang SS, Lipsitch M et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J. Infect. Dis. 195(3), 347-352 (2007).
122. Whitney CG, Klugman KP. Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine. Semin. Pediatr. Infect. Dis. 15(2), 86-93 (2004).
123. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect. Dis. 5(2), 83-93 (2005).
124. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30(1), 100-121 (2000).
125. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin. Infect. Dis. 30(1), 122-140 (2000).
126. Hanage WP. Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiol. 3(1), 23-30 (2008).
127. Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J. Infect. Dis. 190(7), 1203-1211 (2004).
128. Johnson H, Deloria-Knoll M, Levine O et al. Serotype distribution of invasive pneumococcal disease among children globally: Results from the Pneumococcal Global Serotype Project. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008. • Describes the global pneumococcal serotype distributions.
129. Hanquet G, Kissling E, Tarrago D et al. Dynamic changes of three non-vaccine pneumococcal serotypes in Spain, France, Belgium and England & Wales, 1996-2006. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
130. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 25(13), 2406-2412 (2007).
131. Fletcher M, Leeming J, Cartwright K, Finn A; South West of England Invasive Community Acquired Infection Study Group. Childhood empyema: limited potential impact of 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 25(6), 559-560 (2006).
132. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr. Infect. Dis. J. 25(3), 250-254 (2006).
133. Byington C, Mason E, Korgenski K, Daly J, Hulten K. Molecular epidemiology of pediatric pneumococcal empyema in Utah 2001-2007. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
134. Byington C, Pirez MC, Hsieh YC et al. Pediatric parapneumonic empyema and complicated pneumonia after introduction of 7-valent pneumococcal conjugate vaccine (PCV7, Prevenar™). Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases, Reykjavik, Iceland, 8-12 June 2008.
135. Byington CL, Samore MH, Stoddard GJ et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the
136. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin. Infect. Dis. 42(7), 907-914 (2006).
137. Beall B, McEllistrem MC, Gertz RE Jr et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J. Clin. Microbiol. 44(3), 999-1017 (2006).
138. Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason EO Jr; the U.S. Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr. Infect. Dis. J. 25(4), 301-305 (2006).
139. Jacobs MR, Good CE, Beall B, Bajaksouzian S, Windau AR, Whitney CG. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J. Clin. Microbiol. 46(3), 982-990 (2008).
140. Flannery B, Heffernan RT, Harrison LH et al. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann. Intern. Med. 144(1), 1-9 (2006).
141. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B; Active Bacterial Core Surveillance Team. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192(11), 1988-1995 (2005).
142. Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196(9), 1346-1354 (2007).
143. Carvalho MD, Gertz R, Li Z, Moore M, Beall B. Active Bacterial Core Surveillace. Population-based strain surveillance of invasive serotype 19A pneumococci recovered in the United States: 2006. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
144. Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197(7), 1016-1027 (2008).
145. Nunes S, Sá-Leão R, Pereira LC, Lencastre H. Emergence of a serotype 1 Streptococcus pneumoniae lineage colonising healthy children in Portugal in the seven-valent conjugate vaccination era. Clin. Microbiol. Infect. 14(1), 82-84 (2008).
146. Hwa Choi E, Hee Kim S, Wook Eun B et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14(2), 275-281 (2008). •• Demonstrates the increased incidence of serotype 19A before the introduction of PCV?7 in South Korea.
147. Dagan R, Givon-Lavi N, Leibovitz E, Porat N. Increased importance of antibiotic-resistant S. pneumoniae serotype 19A in acute otitis media occurring before introduction of 7-valent pneumococcal conjugate vaccine in southern Israel. Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL , USA, 17-20 September 2007.
148. Pelton SI, Klein JO. The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children. Pediatrics 110(4), 805-814 (2002).
149. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin. Vaccine. Immunol. 13(2), 165-169 (2006).
150. Jodar L, Butler J, Carlone G et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21(23), 3265-3272 (2003).
151. Jokinen JT, Ahman H, Kilpi TM, Mäkelä PH, Käyhty MH. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J. Infect. Dis. 190(3), 545-550 (2004).
152. Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 25(13), 2518-2527 (2007).
153. Schuerman L, Prymula R, Henckaerts I, Poolman J. ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media. Vaccine 25(11), 1962-1968 (2007).
154. Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin. Infect. Dis. 46(5), 726-731 (2008).
155. Nurkka A, Joensuu J, Henckaerts I et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr. Infect. Dis. J. 23(11), 1008-1014 (2004).
156. Gatchalian SR, Borja-Tabora C, Bermal NR et al. A randomised, placebo-controlled study to evaluate the immunogenicity of an 11-valent protein D pneumococcal conjugate vaccine administered as primary vaccination to infants at 6, 10 and 14 weeks of age. Presented at: 19th Annual Meeting of the European Society for Pediatric Infectious Diseases. Istanbul, Turkey, 26-28 March, 2001.
157. Prymula R, Chlibek R, Splino M et al. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines. Vaccine 26(35), 4563-4570 (2008).
158. Schuerman L, Prymula R, Chrobok V, Dieussaert I, Poolman J. Kinetics of the immune response following pneumococcal PD conjugate vaccination. Vaccine 25(11), 1953-1961 (2007).
159. Wysocki J, Galaj A, Omenaca F et al. Immunogenicity of the new 10-valent pneumoccocal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiDCV) in infants after 3-dose priming before 6 months of age. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases, Reykjavik, Iceland, 8-12 June 2008.
160. Knuf M, Grunert D, Wysocki J et al. Safety and reactogenicity of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV). Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
161. Bermal N, Alberto E, Hernandez M et al. Safety and reactogenicity of a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjuagate (PHiD?CV) in Filipino infants. Presented at: 13th International Congress of Infectious Disease, Kuala Lumpur, Malaysia, 19-22 June 2008.
162. Lagos R, Munoz A, Levine M, Ruttimann R, Bernard L, Yarzabal YP. Reactogenicity and immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) candidate co-administered with infanrix HEXA™ in Chilean infants. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases. Reykjavik, Iceland, 8-12 June 2008.
163. Scott DA, Komjathy SF, Hu BT et al. SP. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25(33), 6164-6166 (2007).
164. Scott D, Ruckle J, Dar M, Baker S, Kondoh H, Lockhart S. Phase I trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr. Int. 50(3), 295-299 (2008).
165. Bryant K, Block S, Scott D. Safety and immunogenicity of a toddler dose of a 13-valent pneumococcal conjugate vaccine. Presented at: 6th International Symposium on Pneumococci & Pneumococcal Diseases, Reykjavik, Iceland, 8-12 June 2008.
166. Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. Vaccine 25(16), 2963-2973 (2007)
167. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect. Immun. 75(1), 350-357 (2007).
168. Cao J, Chen D, Xu W et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 25(27), 4996-5005 (2007).
169. Briles DE, Hollingshead S, Brooks-Walter A et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection, Vaccine 18(16), 1707-1711 (2000).
170. Moschioni M, Donati C, Muzzi A et al. Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J. Infect. Dis. 197(6), 888-896 (2008).
171. 197 protein) drug approval information www.fda.gov/cber/label/pneuled021700LB.pdf
172. PneumoADIP www.preventpneumo.org
173. Cumulative weekly number of reports of invasive pneumococcal disease due to serotypes present in Prevenar™: children aged 0-2 years in England and Wales by epidemiological year www.hpa.org.uk